Clinical trial
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for…
NCT00380588 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00380588 |
|---|---|
| Title | Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer |
| Official title | A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Biliary Tract Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, cisplatin |
| Enrollment | 84 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 26, 2006 |
| Last update posted | Nov 20, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: